Endpoint Determination

"Endpoint Determination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Establishment of the level of a quantifiable effect indicative of a biologic process. The evaluation is frequently to detect the degree of toxic or therapeutic effect.

Descriptor ID	D023381
MeSH Number(s)	E05.315
Concept/Terms	Endpoint Determination Endpoint Determination Determination, Endpoint Determinations, Endpoint Endpoint Determinations End Point Determination Determinations, End Point End Point Determinations Point Determinations, End Endpoint Assay Endpoint Assay Assay, Endpoint Assays, Endpoint Endpoint Assays End Point Assay Assay, End Point Assays, End Point End Point Assays Point Assay, End Point Assays, End

Below are MeSH descriptors whose meaning is more general than "Endpoint Determination".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Endpoint Determination [E05.315]

Below are MeSH descriptors whose meaning is related to "Endpoint Determination".

Below are MeSH descriptors whose meaning is more specific than "Endpoint Determination".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Endpoint Determination" by people in this website by year, and whether "Endpoint Determination" was a major or minor topic of these publications.

Bar chart showing 34 publications over 18 distinct years, with a maximum of 4 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2004	0	1	1
2005	1	1	2
2006	0	1	1
2007	1	0	1
2008	1	2	3
2009	1	2	3
2010	0	1	1
2011	0	4	4
2012	1	1	2
2013	0	2	2
2015	0	2	2
2016	1	2	3
2017	2	0	2
2018	0	2	2
2019	0	2	2
2020	1	0	1
2024	1	0	1

Below are the most recent publications written about "Endpoint Determination" by people in Profiles.

Gedde SJ, Vinod K, Bowden EC, Kolomeyer NN, Chopra V, Challa P, Budenz DL, Repka MX, Lum F. Special Commentary: Reporting Clinical Endpoints in Studies of Minimally Invasive Glaucoma Surgery. Ophthalmology. 2025 02; 132(2):141-153.

View in: PubMed
Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, Andr? T. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. Eur J Cancer. 2020 05; 130:63-71.

View in: PubMed
Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, D?az-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Netw Open. 2019 Sep 04; 2(9):e1911750.

View in: PubMed
Alak A, Hohnloser SH, Fr??dorf M, Reilly P, Ezekowitz M, Healey JS, Brueckmann M, Yusuf S, Connolly SJ. Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Europace. 2019 Jul 01; 21(7):1023-1030.

View in: PubMed
Gold MR, Auricchio A, Leclercq C, Lowy J, Rials SJ, Shoda M, Tomassoni G, Yong P, Wold N, Ellenbogen KA. The rationale and design of the SMART CRT trial. Pacing Clin Electrophysiol. 2018 09; 41(9):1212-1216.

View in: PubMed
Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, Leipsic J, Maisano F, Millan X, Nataf P, O'Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis. Eur Heart J. 2018 04 14; 39(15):1224-1245.

View in: PubMed
Roviello G, Andre F, Venturini S, Pistilli B, Curigliano G, Cristofanilli M, Rosellini P, Generali D. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. Eur J Cancer. 2017 11; 86:257-265.

View in: PubMed
Gillam LD, Leipsic J, Weissman NJ. Use of Imaging Endpoints in Clinical Trials. JACC Cardiovasc Imaging. 2017 03; 10(3):296-303.

View in: PubMed
Weintraub WS. Statistical Approaches to Composite?Endpoints. JACC Cardiovasc Interv. 2016 11 28; 9(22):2289-2291.

View in: PubMed
Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK. Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers. Clin Transl Sci. 2016 06; 9(3):176-80.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement